{"transactions":[{"id":1928153,"issuer":{"id":35581,"kind":"organization","name":"Centessa Pharmaceuticals plc","symbol":"CNTA"},"owners":[{"id":114725,"kind":"person","name":"Templeman Thomas","position":1,"cik":"0001654274","reported_name":"Templeman Thomas","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Technology Officer"}}],"security":"Ordinary Shares","published_at":"2023-04-04T17:04:29.000Z","date":"2023-03-31","kind":"tax_withholding","planned":false,"acquired":false,"shares":4103,"price":3.9,"value":16001.7,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represents the number of shares withheld by the Issuer to cover tax withholding obligations in connection with the vesting of restricted share units."}],"balance_after":188244,"source":{"system":"sec-edgar","filing":"0001847903-23-000085","document":"wf-form4_168064224769722.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1654274/000184790323000085/wf-form4_168064224769722.xml","form_type":"4"}},{"id":2032964,"issuer":{"id":35581,"kind":"organization","name":"Centessa Pharmaceuticals plc","symbol":"CNTA"},"owners":[{"id":114725,"kind":"person","name":"Templeman Thomas","position":1,"cik":"0001654274","reported_name":"Templeman Thomas","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Technology Officer"}}],"security":"Share Option (right to buy)","published_at":"2023-02-03T17:14:23.000Z","date":"2023-02-01","kind":"grant","acquired":true,"shares":90000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"1/48th of the shares subject to such option shall vest and become exercisable in equal monthly installments with the first installment vesting on March 1, 2023."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."}],"balance_after":90000,"derivative":{"exercise_price":3.85,"expiration_date":"2033-02-01","underlying":"Ordinary Shares","underlying_shares":90000},"source":{"system":"sec-edgar","filing":"0001847903-23-000050","document":"wf-form4_167546244249524.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1654274/000184790323000050/wf-form4_167546244249524.xml","form_type":"4"}},{"id":2032963,"issuer":{"id":35581,"kind":"organization","name":"Centessa Pharmaceuticals plc","symbol":"CNTA"},"owners":[{"id":114725,"kind":"person","name":"Templeman Thomas","position":1,"cik":"0001654274","reported_name":"Templeman Thomas","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Technology Officer"}}],"security":"Ordinary Shares","published_at":"2023-02-03T17:14:23.000Z","date":"2023-02-01","kind":"grant","acquired":true,"shares":60400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."},{"field":"shares","element":"transactionShares","label":"F2","text":"The shares reported in this transaction represent Restricted Share Units (\"RSUs\") issued under the Centessa Pharmaceuticals plc Amended and Restated 2021 Stock Option and Incentive Plan. Each RSU represents the contingent right to receive one Ordinary Share of the Issuer. The RSUs shall vest and be settled in four equal annual installments with the first such annual vesting being on February 1, 2024."}],"balance_after":192347,"source":{"system":"sec-edgar","filing":"0001847903-23-000050","document":"wf-form4_167546244249524.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1654274/000184790323000050/wf-form4_167546244249524.xml","form_type":"4"}},{"id":2054727,"issuer":{"id":35581,"kind":"organization","name":"Centessa Pharmaceuticals plc","symbol":"CNTA"},"owners":[{"id":114725,"kind":"person","name":"Templeman Thomas","position":1,"cik":"0001654274","reported_name":"Templeman Thomas","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Technology Officer"}}],"security":"Ordinary Shares","published_at":"2023-01-13T17:47:24.000Z","date":"2022-09-30","kind":"tax_withholding","acquired":false,"shares":5382,"price":4.25,"value":22873.5,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represents the number of shares withheld by the Issuer to cover tax withholding obligations in connection with the vesting of restricted share units."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Shares held by the Reporting Person after the reported transaction herein and does not include shares acquired or disposed of in subsequent reported transactions after September 30, 2022."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"As of year end December 31, 2022, the Reporting Person held 131,947 shares directly."}],"balance_after":134868,"source":{"system":"sec-edgar","filing":"0001847903-23-000030","document":"wf-form4_167365002958466.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1654274/000184790323000030/wf-form4_167365002958466.xml","form_type":"4"}},{"id":2067635,"issuer":{"id":35581,"kind":"organization","name":"Centessa Pharmaceuticals plc","symbol":"CNTA"},"owners":[{"id":114725,"kind":"person","name":"Templeman Thomas","position":1,"cik":"0001654274","reported_name":"Templeman Thomas","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Technology Officer"}}],"security":"Ordinary Shares","published_at":"2023-01-04T19:26:57.000Z","date":"2022-12-31","kind":"tax_withholding","acquired":false,"shares":2921,"price":3.1,"value":9055.1,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represents the number of shares withheld by the Issuer to cover tax withholding obligations in connection with the vesting of restricted share units."}],"balance_after":137329,"source":{"system":"sec-edgar","filing":"0001847903-23-000014","document":"wf-form4_167287839696137.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1654274/000184790323000014/wf-form4_167287839696137.xml","form_type":"4"}},{"id":2144619,"issuer":{"id":35581,"kind":"organization","name":"Centessa Pharmaceuticals plc","symbol":"CNTA"},"owners":[{"id":114725,"kind":"person","name":"Templeman Thomas","position":1,"cik":"0001654274","reported_name":"Templeman Thomas","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Technology Officer"}}],"security":"Ordinary Shares","published_at":"2022-10-04T17:06:32.000Z","date":"2022-10-03","kind":"sale","acquired":false,"shares":2455,"price":3.9501,"value":9697.4955,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."},{"field":"kind","element":"transactionCoding","label":"F2","text":"The sales reported represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted share units and do not represent discretionary trades by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.765 to $4.0499, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":135792,"source":{"system":"sec-edgar","filing":"0001847903-22-000068","document":"wf-form4_166491752809560.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1654274/000184790322000068/wf-form4_166491752809560.xml","form_type":"4"}},{"id":2144618,"issuer":{"id":35581,"kind":"organization","name":"Centessa Pharmaceuticals plc","symbol":"CNTA"},"owners":[{"id":114725,"kind":"person","name":"Templeman Thomas","position":1,"cik":"0001654274","reported_name":"Templeman Thomas","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Technology Officer"}}],"security":"Ordinary Shares","published_at":"2022-10-04T17:06:32.000Z","date":"2022-09-30","kind":"sale","acquired":false,"shares":2003,"price":4.0674,"value":8147.0022,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."},{"field":"kind","element":"transactionCoding","label":"F2","text":"The sales reported represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted share units and do not represent discretionary trades by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.93 to $4.255, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":138247,"source":{"system":"sec-edgar","filing":"0001847903-22-000068","document":"wf-form4_166491752809560.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1654274/000184790322000068/wf-form4_166491752809560.xml","form_type":"4"}},{"id":2211946,"issuer":{"id":35581,"kind":"organization","name":"Centessa Pharmaceuticals plc","symbol":"CNTA"},"owners":[{"id":114725,"kind":"person","name":"Templeman Thomas","position":1,"cik":"0001654274","reported_name":"Templeman Thomas","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Technology Officer"}}],"security":"Ordinary Shares","published_at":"2022-07-06T18:15:36.000Z","date":"2022-07-01","kind":"grant","acquired":true,"shares":140000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."},{"field":"shares","element":"transactionShares","label":"F2","text":"The shares reported in this transaction represent Restricted Share Units (\"RSUs\") issued under the Centessa Pharmaceuticals plc Amended and Restated 2021 Stock Option and Incentive Plan. Each RSU represents the contingent right to receive one Ordinary Share of the Issuer. The RSUs shall vest and be settled in 10 equal quarterly instalments with the first such quarterly vesting being on September 30, 2022."}],"balance_after":140250,"source":{"system":"sec-edgar","filing":"0000899243-22-025472","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1654274/000089924322025472/doc4.xml","form_type":"4"}},{"id":2413992,"issuer":{"id":35581,"kind":"organization","name":"Centessa Pharmaceuticals plc","symbol":"CNTA"},"owners":[{"id":114725,"kind":"person","name":"Templeman Thomas","position":1,"cik":"0001654274","reported_name":"Templeman Thomas","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Technology Officer"}}],"security":"Share Option (right to buy)","published_at":"2022-02-03T18:30:29.000Z","date":"2022-02-01","kind":"grant","acquired":true,"shares":140000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"11,664 shares subject to such option shall vest and become exercisable on June 1,2022 and the remaining 128,336 shares subject to such option shall vest and become exercisable in 44 substantially equal installments on each monthly anniversary thereafter."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F2","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."}],"balance_after":140000,"derivative":{"exercise_price":9.53,"expiration_date":"2032-02-01","underlying":"Ordinary Shares","underlying_shares":140000},"source":{"system":"sec-edgar","filing":"0000899243-22-004683","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1654274/000089924322004683/doc4.xml","form_type":"4"}},{"id":2680955,"issuer":{"id":35581,"kind":"organization","name":"Centessa Pharmaceuticals plc","symbol":"CNTA"},"owners":[{"id":114725,"kind":"person","name":"Templeman Thomas","position":1,"cik":"0001654274","reported_name":"Templeman Thomas","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Technology Officer"}}],"security":"Share Option (right to buy)","published_at":"2021-06-04T17:00:48.000Z","date":"2021-04-20","kind":"grant","acquired":true,"shares":500338,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"On May 20, 2021, the Issuer effected a share capital reorganization, which had the effect of a one for two reverse share split of the Issuer's share capital (\"Share Split\"). This amount has been adjusted to give effect to the Share Split."},{"field":"kind","element":"transactionCoding","label":"F3","text":"This transaction occurred prior to the effectiveness of the Issuer's registration under Section 12 of the Securities Exchange Act of 1934 and is being reported on Form 4 solely for purposes of compliance with Rule 16a-2(a) under the Securities Exchange Act of 1934, as amended. The securities covered by such transaction were previously included on the Reporting Person's Form 3"},{"field":"shares","element":"transactionShares","label":"F2","text":"On May 20, 2021, the Issuer effected a share capital reorganization, which had the effect of a one for two reverse share split of the Issuer's share capital (\"Share Split\"). This amount has been adjusted to give effect to the Share Split."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"25% of the shares subject to such option shall vest and become exercisable on May 17, 2022 and the remaining 75% of the shares subject to such option shall vest and become exercisable in 36 monthly installments on the first day of each month thereafter."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F5","text":"Represented A Ordinary Shares that were redesignated as Ordinary Shares immediately prior to the closing of the initial public offering."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F2","text":"On May 20, 2021, the Issuer effected a share capital reorganization, which had the effect of a one for two reverse share split of the Issuer's share capital (\"Share Split\"). This amount has been adjusted to give effect to the Share Split."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"On May 20, 2021, the Issuer effected a share capital reorganization, which had the effect of a one for two reverse share split of the Issuer's share capital (\"Share Split\"). This amount has been adjusted to give effect to the Share Split."}],"balance_after":500338,"derivative":{"exercise_price":9.42,"expiration_date":"2031-04-20","underlying":"Ordinary Shares","underlying_shares":500338},"source":{"system":"sec-edgar","filing":"0000899243-21-022068","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1654274/000089924321022068/doc4.xml","form_type":"4"}},{"id":2680954,"issuer":{"id":35581,"kind":"organization","name":"Centessa Pharmaceuticals plc","symbol":"CNTA"},"owners":[{"id":114725,"kind":"person","name":"Templeman Thomas","position":1,"cik":"0001654274","reported_name":"Templeman Thomas","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Technology Officer"}}],"security":"Ordinary Shares","published_at":"2021-06-04T17:00:48.000Z","date":"2021-06-02","kind":"purchase","acquired":true,"shares":250,"price":20,"value":5000.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."}],"balance_after":250,"source":{"system":"sec-edgar","filing":"0000899243-21-022068","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1654274/000089924321022068/doc4.xml","form_type":"4"}},{"id":2863792,"issuer":{"id":4384,"kind":"organization","name":"Nuvation Bio Inc."},"owners":[{"id":114725,"kind":"person","name":"Templeman Thomas","position":1,"cik":"0001654274","reported_name":"Templeman Thomas","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Pharmaceutical Ops"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-02-12T22:48:19.000Z","date":"2021-02-10","kind":"grant","acquired":true,"shares":398935,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Received pursuant to the Agreement and Plan of Merger, dated as of October 20, 2020, by and among Panacea Acquisition Corp. (\"Panacea\") and Panacea Merger Subsidiary Corp., a direct, wholly-owned subsidiary of Panacea (\"Merger Sub\"), and Nuvation Bio Inc. (\"Legacy Nuvation\") pursuant to which, as a result of a merger between Legacy Nuvation and Merger Sub, Legacy Nuvation became a direct, wholly-owned subsidiary of Panacea, which subsequently changed its name to Nuvation Bio Inc. (the \"Issuer\")."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Received in exchange for an option to purchase 398,935 shares of Legacy Nuvation Class A Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Options vest as to 25% on July 1, 2020 and in equal monthly installments thereafter over the following three years."}],"balance_after":398935,"derivative":{"exercise_price":1.74,"expiration_date":"2030-01-21","underlying":"Class A Common Stock","underlying_shares":398935},"source":{"system":"sec-edgar","filing":"0001209191-21-010339","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1811063/000120919121010339/doc4.xml","form_type":"4"}},{"id":2863791,"issuer":{"id":4384,"kind":"organization","name":"Nuvation Bio Inc."},"owners":[{"id":114725,"kind":"person","name":"Templeman Thomas","position":1,"cik":"0001654274","reported_name":"Templeman Thomas","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Pharmaceutical Ops"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-02-12T22:48:19.000Z","date":"2021-02-10","kind":"grant","acquired":true,"shares":398935,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Received pursuant to the Agreement and Plan of Merger, dated as of October 20, 2020, by and among Panacea Acquisition Corp. (\"Panacea\") and Panacea Merger Subsidiary Corp., a direct, wholly-owned subsidiary of Panacea (\"Merger Sub\"), and Nuvation Bio Inc. (\"Legacy Nuvation\") pursuant to which, as a result of a merger between Legacy Nuvation and Merger Sub, Legacy Nuvation became a direct, wholly-owned subsidiary of Panacea, which subsequently changed its name to Nuvation Bio Inc. (the \"Issuer\")."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Received in exchange for an option to purchase 398,935 shares of Legacy Nuvation Class A Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Options vest as to 20% on October 5, 2023, 20% on October 5, 2023 and 60% on October 5, 2025, subject to achievement of performance criteria."}],"balance_after":398935,"derivative":{"exercise_price":4.6,"expiration_date":"2030-10-04","underlying":"Class A Common Stock","underlying_shares":398935},"source":{"system":"sec-edgar","filing":"0001209191-21-010339","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1811063/000120919121010339/doc4.xml","form_type":"4"}}]}